<span id="hs_cos_wrapper_module_1395325065960295" class= "hs_cos_wrapper hs_cos_wrapper_widget_container hs_cos_wrapper_type_widget_container" data-hs-cos-type="widget_container" data-hs-cos-general-type= "widget_container">According to a global study by Mergermarket and Reed Smith, 94 percent of senior life sciences executives plan to make an acquisition in 2016, so biotech firms need to do everything possible to make sure they are properly positioned to get the most value for their asset.

According to a global study by Mergermarket and Reed Smith, 94 percent of senior life sciences executives plan to make an acquisition in 2016, so biotech firms need to do everything possible to make sure they are properly positioned to get the most value for their asset.

According to a global study by Mergermarket and Reed Smith, 94 percent of senior life sciences executives plan to make an acquisition in 2016, so biotech firms need to do everything possible to make sure they are properly positioned to get the most value for their asset. &nbsp;

9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)

YourEncore's Pharmcast is your weekly dose of wisdom from today's top life science minds. Each week in the Pharmcast, we talk with top industry experts in our network or beyond about hot industry topics, leadership, and the path to success.

Share 9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)

Sign up to save your podcasts

9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)

9 Biotech Valuation Killers (Ep. 3 of The Pharmcast)